All In Biotech

Drug Trial Radar · NCT05338099

Determine the Safety and Dose of EN001 in Patients With Duchenne Muscular Dystrophy(DMD)

Open-label, Dose-escalation, Phase 1 Clinical Trial to Determine the Safety and Dose of EN001 in Patients With Duchenne Muscular Dystrophy(DMD)

Last checked: Nov 20, 2026Latest source record: Aug 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

7

Actual

Start

Jan 18, 2022

Primary completion

Dec 28, 2022

Study completion Dec 28, 2022

Sponsor

Lead sponsor
ENCellIndustry
Sponsor type
Industry
First posted
Apr 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 2 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Open-label, Dose-escalation, Phase 1 Clinical Trial to Determine the Safety and Dose of EN001 in Patients with Duchenne Muscular Dystrophy(DMD)

Conditions

  • Duchenne Muscular Dystrophy

Interventions

  • EN001Drug

    EN001 intravenously (IV) in the treatment of Duchenne Muscular Dystrophy (DMD) Dosage for each group is as follows. Dose group A (Low dose): 5.0x10\^5 cells/kg

  • EN001Drug

    EN001 intravenously (IV) in the treatment of Duchenne Muscular Dystrophy (DMD) Dosage for each group is as follows. Dose group B (High dose): 2.5x10\^6 cells/kg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants of any Adverse Events (AEs)/Serious Adverse Events (SAEs) related investigational productTime frame: Week 12 after treatment
  2. Determination of Dose-limiting toxicity (DLT) levels of EN001Time frame: Up to Week 2 after dosing on Day 0
  3. Determination of Maximum tolerated dose (MTD) levels of EN001Time frame: Up to Week 2 after dosing on Day 0
  4. Number of participants with Vital Signs abnormalitiesTime frame: Week 12 after screening
  5. Number of participants with clinically significant abnormalities of Physical ExaminationsTime frame: From screening up to Week 12
  6. Number of participants with abnormalities of Laboratory ParametersTime frame: From screening up to Week 12
  7. Number of participants with abnormalities of 12-lead Electrocardiography (ECG)Time frame: From screening to baseline on Day 0 (Predose to end of infusion and 90 min after completion of infusion)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Samsung Medical Center

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.